Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HeraMEDASX:HMD Equity-to-Asset is 0.62 as of Dec. 2025, which is at its 10-year median of 0.62. The stock has 2 warning signs investors should review. Among 851 Medical Devices & Instruments companies, HeraMED ranks worse than 52.53% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. HeraMED's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$0.93 Mil. HeraMED's Total Assets for the quarter that ended in Dec. 2025 was A$1.49 Mil.
Therefore, HeraMED's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.62.
The historical rank and industry rank for HeraMED's Equity-to-Asset or its related term are showing as below:
ASX:HMD'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02 Med: 0.62 Max: 0.77
Current: 0.62
During the past 8 years, the highest Equity to Asset Ratio of HeraMED was 0.77. The lowest was -0.02. And the median was 0.62.
ASX:HMD's Equity-to-Asset is ranked worse than 52.53% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs ASX:HMD: 0.62
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
HeraMED Equity-to-Asset Related Terms
HeraMED Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for HeraMED's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:HMD vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, HeraMED's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeraMED Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where HeraMED's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
HeraMED's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeraMED (ASX:HMD) has a Equity-to-Asset of 0.62 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on HeraMED and its competitors. This is near median its historical median of 0.62. According to the industry distribution chart, HeraMED ranks #447 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 52.5%.
Is HeraMED's Equity-to-Asset too high?
HeraMED's current Equity-to-Asset of 0.62 is near median its 10-year median of 0.62. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. HeraMED's value of 0.62 is 3.1% below this industry median. Based on the distribution chart, HeraMED ranks #447 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does HeraMED's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HeraMED ranks #447 out of 851 companies for Equity-to-Asset. This places HeraMED in the lower half of its industry. The industry median Equity-to-Asset is 0.64. HeraMED's value of 0.62 is 3.1% below this benchmark. While the company's 10-year median is 0.62 vs. the industry median of 0.64, HeraMED has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeraMED's current Equity-to-Asset of 0.62 is 3.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on HeraMED and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeraMED's current Equity-to-Asset is 0.62, which is near median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.04 — trading 85% above its estimated fair value. The current Equity-to-Asset is 0.62, which is near median its 10-year median of 0.62 and 3.1% below the Medical Devices & Instruments industry median of 0.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current Equity-to-Asset is 0.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HMD has been successfully added to your 
